127 related articles for article (PubMed ID: 25139703)
1. Staphylococcus aureus bio-products: new biological roles for a pleurodesis agent.
Psallidas I; Stathopoulos GT
Respirology; 2014 Oct; 19(7):948-9. PubMed ID: 25139703
[No Abstract] [Full Text] [Related]
2. A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma.
Lansley SM; Varano Della Vergiliana JF; Cleaver AL; Ren SH; Segal A; Xu MY; Lee YC
Respirology; 2014 Oct; 19(7):1025-33. PubMed ID: 25123375
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Nivolumab on Sarcomatoid Malignant Pleural Mesothelioma With Eosinophilia and Eosinophilic Pleural Effusion.
Yamazoe M; Ozasa H; Kim YH
J Thorac Oncol; 2019 Nov; 14(11):e251-e253. PubMed ID: 31668324
[No Abstract] [Full Text] [Related]
5. Malignant mesothelioma with fungating masses and multiple sites involvement.
Sim JK; Oh JY; Min KH; Hur GY; Shim JJ; Kang KH; Lee SY
Clin Respir J; 2017 Jul; 11(4):524-528. PubMed ID: 26364960
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
[TBL] [Abstract][Full Text] [Related]
7. Proton Beam Therapy and Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma.
McCusker MG; Scilla KA; Simone CB; Sachdeva A; Miller KD; Burke AP; Rolfo C
J Thorac Oncol; 2019 Sep; 14(9):e185-e187. PubMed ID: 31235402
[No Abstract] [Full Text] [Related]
8. Diagnosis and treatment of malignant pleural mesothelioma.
Rodríguez Panadero F
Arch Bronconeumol; 2015 Apr; 51(4):177-84. PubMed ID: 25059587
[TBL] [Abstract][Full Text] [Related]
9. A Case of Diffuse Intrapulmonary Malignant Mesothelioma.
Kumazawa M; Arakawa H; Shiobara T; Ishii Y; Nakazato Y; Kaji Y
J Thorac Imaging; 2019 Nov; 34(6):W147-W149. PubMed ID: 31658210
[No Abstract] [Full Text] [Related]
10. Video-assisted biopsy and talc pleurodesis for malignant pleural mesothelioma.
Maat A; Abdullah S; Schouten G; Cornelissen R; Bogers A; Mahtab E
Multimed Man Cardiothorac Surg; 2020 Jul; 2020():. PubMed ID: 32633902
[TBL] [Abstract][Full Text] [Related]
11. Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib.
Agatsuma N; Yasuda Y; Ozasa H
J Thorac Oncol; 2017 Sep; 12(9):e141-e143. PubMed ID: 28838714
[No Abstract] [Full Text] [Related]
12. Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
Blomberg C; Nilsson J; Holgersson G; Edlund P; Bergqvist M; Adwall L; Ekman S; Brattström D; Bergström S
Anticancer Res; 2015 May; 35(5):2493-501. PubMed ID: 25964522
[TBL] [Abstract][Full Text] [Related]
13. IASLC 2020 World Conference on Lung Cancer.
Venkatesan P
Lancet Respir Med; 2020 Oct; 8(10):e76. PubMed ID: 32866439
[No Abstract] [Full Text] [Related]
14. Resveratrol and cisplatin in a malignant mesothelioma cell model.
Chirumbolo S; Bjørklund G
Food Chem Toxicol; 2016 Dec; 98(Pt B):308-309. PubMed ID: 27856297
[No Abstract] [Full Text] [Related]
15. Malignant Mesothelioma and Delivery of Polyphenols.
Bishop KS; Braakhuis AJ; Ferguson LR
Nutrients; 2016 Jun; 8(6):. PubMed ID: 27271656
[TBL] [Abstract][Full Text] [Related]
16. Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment.
Vigani A; Pistillo MP; Fontana V; Giannoni U; Rosenberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
J Thorac Oncol; 2018 Aug; 13(8):e143-e145. PubMed ID: 30049376
[No Abstract] [Full Text] [Related]
17. Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators.
Hamaidia M; Staumont B; Duysinx B; Louis R; Willems L
Curr Top Med Chem; 2016; 16(7):777-87. PubMed ID: 26303419
[TBL] [Abstract][Full Text] [Related]
18. Not everything is what it seems: malignant pleural mesothelioma mimicking lung cancer.
Prisciandaro E; Girelli L; Rampinelli C; Ghioni M; Spaggiari L
Adv Respir Med; 2019; 87(6):265-267. PubMed ID: 31970729
[TBL] [Abstract][Full Text] [Related]
19. Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study.
Buikhuisen WA; Qayyum F; Armato SG; Baas P
Lung Cancer; 2019 Dec; 138():139-140. PubMed ID: 31733933
[No Abstract] [Full Text] [Related]
20. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
